<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a 10-year follow-up on 52 patients with raised levels of anticardiolipin antibodies (aCL) who were first seen at our tertiary referral centre in 1986 </plain></SENT>
<SENT sid="1" pm="."><plain>The clinical and serological features of these 52 patients are described </plain></SENT>
<SENT sid="2" pm="."><plain>Thirty-one patients had the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) in 1986 </plain></SENT>
<SENT sid="3" pm="."><plain>Nine of these patients (29%) had further thrombotic events during the follow-up period </plain></SENT>
<SENT sid="4" pm="."><plain>Of the other 21 aCL positive patients without clinical manifestations of APS, 11 (52%) developed the syndrome over this period </plain></SENT>
<SENT sid="5" pm="."><plain>Five patients (10%) died during the follow-up </plain></SENT>
<SENT sid="6" pm="."><plain>Close monitoring of patients with <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue diseases</z:e> and aCL is essential as the likelihood of developing <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> is high </plain></SENT>
</text></document>